KR20010012256A - 프로테아제 억제제 - Google Patents
프로테아제 억제제 Download PDFInfo
- Publication number
- KR20010012256A KR20010012256A KR1019997010207A KR19997010207A KR20010012256A KR 20010012256 A KR20010012256 A KR 20010012256A KR 1019997010207 A KR1019997010207 A KR 1019997010207A KR 19997010207 A KR19997010207 A KR 19997010207A KR 20010012256 A KR20010012256 A KR 20010012256A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- amino
- leucine
- tetrahydrofuran
- ylcarbonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4575897P | 1997-05-06 | 1997-05-06 | |
US60/045,758 | 1997-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20010012256A true KR20010012256A (ko) | 2001-02-15 |
Family
ID=21939723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019997010207A KR20010012256A (ko) | 1997-05-06 | 1998-05-06 | 프로테아제 억제제 |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1003846A4 (fr) |
JP (1) | JP2001525804A (fr) |
KR (1) | KR20010012256A (fr) |
CN (1) | CN1255161A (fr) |
AR (1) | AR013079A1 (fr) |
AU (1) | AU7562598A (fr) |
BR (1) | BR9809306A (fr) |
CA (1) | CA2288868A1 (fr) |
CO (1) | CO4950618A1 (fr) |
HU (1) | HUP0002247A3 (fr) |
IL (1) | IL132088A0 (fr) |
NO (1) | NO995434L (fr) |
NZ (1) | NZ337889A (fr) |
PE (1) | PE71599A1 (fr) |
PL (1) | PL336856A1 (fr) |
TR (1) | TR199902766T2 (fr) |
UY (1) | UY25143A1 (fr) |
WO (1) | WO1998050533A1 (fr) |
ZA (1) | ZA983762B (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO5150165A1 (es) * | 1998-11-13 | 2002-04-29 | Smithkline Beecham Plc | Inhibidores de proteasa: tipo catepsina k |
DZ3083A1 (fr) * | 1999-02-19 | 2004-06-02 | Smithkline Beecham Corp | Composés nouveaux inhibiteurs de protéases, procédé pour leur préparation et compositions pharmaceutiques les conentant. |
GB9911417D0 (en) * | 1999-05-18 | 1999-07-14 | Peptide Therapeutics Ltd | Furanone derivatives as inhibitors of cathepsin s |
EP1232155A4 (fr) * | 1999-11-10 | 2002-11-20 | Smithkline Beecham Corp | Inhibiteurs de protease |
US20040024000A1 (en) * | 2000-10-19 | 2004-02-05 | Rajeshwar Singh | Dihydropyrimidine derivatives as cysteine protease inhibitors |
EP1345931A2 (fr) * | 2000-11-17 | 2003-09-24 | Medivir UK Ltd | Inhibiteurs de cysteine protease |
DE60118793T2 (de) * | 2000-11-17 | 2007-04-26 | Medivir Ab | Cystein protease inhibitoren |
PT1362052E (pt) | 2001-01-17 | 2007-04-30 | Amura Therapeutics Ltd | Inibidores de cruzipaína e de outras proteases de cisteína |
US7132449B2 (en) | 2001-01-17 | 2006-11-07 | Amura Therapeutics Limited | Inhibitors of cruzipain and other cysteine proteases |
CA2435117A1 (fr) * | 2001-01-17 | 2002-07-25 | Amura Therapeutics Limited | 2-carbonylaminocetones cycliques, inhibiteurs de la cruzipain et autres cysteine proteases |
JP2004520365A (ja) | 2001-01-17 | 2004-07-08 | アミュラ テラピューティクス リミテッド | クルジパインおよび他のシステインプロテアーゼの阻害剤 |
US6841571B2 (en) * | 2001-10-29 | 2005-01-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cysteine proteases |
CN100354276C (zh) * | 2002-07-16 | 2007-12-12 | 阿姆拉医疗有限公司 | 生物活性化合物 |
KR100962972B1 (ko) | 2002-07-26 | 2010-06-09 | 주식회사유한양행 | 1-페닐피페리딘-3-온 유도체 및 그의 제조방법 |
WO2005041684A2 (fr) | 2003-08-06 | 2005-05-12 | Senomyx Inc. | Saveurs, modificateurs de saveur, agents gustatifs, rehausseurs de gout, agents gustatifs et/ou rehausseurs umami ou sucres, et utilisation correspondante |
AU2016206281B2 (en) * | 2003-08-06 | 2017-11-30 | Senomyx, Inc. | Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof |
BRPI0506719A (pt) * | 2004-01-08 | 2007-05-02 | Medivir Ab | composto, composição farmacêutica, e, uso de um composto |
EP1931657B1 (fr) * | 2005-08-17 | 2013-12-25 | Merck Sharp & Dohme Corp. | Nouveaux ligands de kinases a base de quinoline a affinite elevee |
GB0614042D0 (en) | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
AU2008266228A1 (en) * | 2007-06-13 | 2008-12-24 | Bristol-Myers Squibb Company | Dipeptide analogs as coagulation factor inhibitors |
US7893067B2 (en) | 2007-06-27 | 2011-02-22 | Medivir Ab | Cysteine protease inhibitors |
WO2009087379A2 (fr) | 2008-01-09 | 2009-07-16 | Amura Therapeutics Limited | Composés |
GB0817424D0 (en) * | 2008-09-24 | 2008-10-29 | Medivir Ab | Protease inhibitors |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3190431B2 (ja) * | 1991-07-01 | 2001-07-23 | 三菱化学株式会社 | ケトン誘導体 |
JPH05140063A (ja) * | 1991-11-19 | 1993-06-08 | Suntory Ltd | ジペプチド誘導体及びそれを有効成分とする骨疾患の予防及び治療剤 |
CA2111930A1 (fr) * | 1992-12-25 | 1994-06-26 | Ryoichi Ando | Derives d'aminocetones |
JP2848232B2 (ja) * | 1993-02-19 | 1999-01-20 | 武田薬品工業株式会社 | アルデヒド誘導体 |
JP3599287B2 (ja) * | 1993-04-28 | 2004-12-08 | 三菱化学株式会社 | スルホンアミド誘導体 |
US5403952A (en) * | 1993-10-08 | 1995-04-04 | Merck & Co., Inc. | Substituted cyclic derivatives as novel antidegenerative agents |
PL328877A1 (en) * | 1995-10-30 | 1999-03-01 | Smithkline Beecham Corp | Method of inhibiting cathepsin k |
TW448172B (en) * | 1996-03-08 | 2001-08-01 | Pharmacia & Upjohn Co Llc | Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation |
WO1998004539A1 (fr) * | 1996-07-29 | 1998-02-05 | Mitsubishi Chemical Corporation | Derives heterocycliques oxygenes |
-
1998
- 1998-05-04 AR ARP980102069A patent/AR013079A1/es unknown
- 1998-05-05 PE PE1998000336A patent/PE71599A1/es not_active Application Discontinuation
- 1998-05-05 ZA ZA983762A patent/ZA983762B/xx unknown
- 1998-05-06 NZ NZ337889A patent/NZ337889A/en unknown
- 1998-05-06 HU HU0002247A patent/HUP0002247A3/hu unknown
- 1998-05-06 BR BR9809306-1A patent/BR9809306A/pt not_active Application Discontinuation
- 1998-05-06 EP EP98923299A patent/EP1003846A4/fr not_active Withdrawn
- 1998-05-06 CN CN98804791A patent/CN1255161A/zh active Pending
- 1998-05-06 IL IL13208898A patent/IL132088A0/xx unknown
- 1998-05-06 CO CO98024945A patent/CO4950618A1/es unknown
- 1998-05-06 PL PL98336856A patent/PL336856A1/xx unknown
- 1998-05-06 KR KR1019997010207A patent/KR20010012256A/ko not_active Application Discontinuation
- 1998-05-06 WO PCT/US1998/003200 patent/WO1998050533A1/fr not_active Application Discontinuation
- 1998-05-06 CA CA002288868A patent/CA2288868A1/fr not_active Abandoned
- 1998-05-06 JP JP54804998A patent/JP2001525804A/ja active Pending
- 1998-05-06 TR TR1999/02766T patent/TR199902766T2/xx unknown
- 1998-05-06 AU AU75625/98A patent/AU7562598A/en not_active Abandoned
- 1998-08-17 UY UY25143A patent/UY25143A1/es unknown
-
1999
- 1999-11-05 NO NO995434A patent/NO995434L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1003846A4 (fr) | 2002-11-13 |
IL132088A0 (en) | 2001-03-19 |
AU7562598A (en) | 1998-11-27 |
AR013079A1 (es) | 2000-12-13 |
HUP0002247A3 (en) | 2003-01-28 |
PL336856A1 (en) | 2000-07-17 |
WO1998050533A1 (fr) | 1998-11-12 |
ZA983762B (en) | 1998-11-06 |
UY25143A1 (es) | 1998-11-27 |
NZ337889A (en) | 2001-09-28 |
HUP0002247A2 (hu) | 2001-05-28 |
NO995434D0 (no) | 1999-11-05 |
CA2288868A1 (fr) | 1998-11-12 |
NO995434L (no) | 1999-11-05 |
EP1003846A1 (fr) | 2000-05-31 |
CO4950618A1 (es) | 2000-09-01 |
PE71599A1 (es) | 1999-09-15 |
TR199902766T2 (xx) | 2000-02-21 |
CN1255161A (zh) | 2000-05-31 |
JP2001525804A (ja) | 2001-12-11 |
BR9809306A (pt) | 2000-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20010012256A (ko) | 프로테아제 억제제 | |
US20040044201A1 (en) | Protease inhibitors | |
EP0923535A1 (fr) | Inhibiteurs de cysteine protease | |
JP2002518444A (ja) | プロテアーゼ阻害薬 | |
JP2002537297A (ja) | プロテアーゼ阻害剤 | |
EP1079821A1 (fr) | Inhibiteurs de la protease | |
WO2000029408A1 (fr) | Inhibiteurs de morpholino-ethoxybenzofuran protease | |
US6566373B2 (en) | Protease inhibitors | |
EP1173429A1 (fr) | Inhibiteurs de protease | |
JP2002517485A (ja) | プロテアーゼ阻害剤 | |
JP2002533452A (ja) | プロテアーゼ阻害剤 | |
EP1161237A1 (fr) | Inhibiteurs de protease | |
JP2004527575A (ja) | プロテアーゼ阻害物質 | |
US20050256100A1 (en) | Protease inhibitors | |
CZ388799A3 (cs) | Inhibitory proteasy | |
US20020165222A1 (en) | Protease inhibitors | |
KR20040004445A (ko) | 프로테아제 억제제 | |
MXPA99010254A (en) | Protease inhibitors | |
US20050256105A1 (en) | Protease inhibitors | |
US20050203084A1 (en) | Protease inhibitors | |
US7109233B2 (en) | Protease inhibitors | |
US20020082426A1 (en) | Protease inhibitors | |
EP1511492A2 (fr) | Inhibiteurs de protease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |